Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Identifying pCR After Neoadjuvant Chemotherapy: The Key to Treatment De-escalation in Breast Cancer

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kuerer HM, Newman LA, Buzdar AU, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am. 1998;4(4): 230–6.

  2. Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg. 2018;153(12):1120–6.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Samiei S, van Nijnatten TJA, de Munck L, et al. Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg. 2020;271(3):574–80.

  4. Lim DW, Greene BD, Look Hong NJ. Relationship between breast and axillary pathologic complete response in women receiving neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10519-8.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Heil J, Kuerer HM, Pfob A, et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020;31(1):61–71.

  6. Omission of radiation in patients with Her-2 positive breast cancer. ClinicalTrials.gov identifier: NCT03460067. Updated May 11, 2021. Available at: https://www.clinicaltrials.gov/ct2/show/NCT03460067. Accessed 7 Aug 2021.

Download references

Acknowledgment

D.W. Lim is supported by a Canadian Institutes of Health Research (CIHR) Fellowship from 2019 to 2022, the Helen Marion Walker-Soroptimist Women’s Health Research Scholarship from Soroptimist International of Toronto, and the Canadian Cancer Society (CCS) Chair in Breast Cancer Research at Women’s College Research Institute at Women’s College Hospital (Toronto, Ontario, Canada).

Author information

Authors and Affiliations

  1. Women’s College Research Institute, Women’s College Hospital, Toronto, ON, Canada

    David W. Lim MDCM, MEd, PhD

  2. Department of Surgery, Women’s College Hospital, Toronto, ON, Canada

    David W. Lim MDCM, MEd, PhD

  3. Division of General Surgery, Department of Surgery, University Health Network, Toronto, ON, Canada

    David W. Lim MDCM, MEd, PhD

  4. Division of General Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada

    Nicole J. Look Hong MD, MSc

  5. Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, ON, Canada

    Nicole J. Look Hong MD, MSc

  6. Division of Surgical Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

    Nicole J. Look Hong MD, MSc

Authors
  1. David W. Lim MDCM, MEd, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicole J. Look Hong MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David W. Lim MDCM, MEd, PhD.

Ethics declarations

Disclosure

David W. Lim has no conflicts of interest. Nicole J. Look Hong is a consultation for MOLLI® Surgical.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lim, D.W., Hong, N.J.L. ASO Author Reflections: Identifying pCR After Neoadjuvant Chemotherapy: The Key to Treatment De-escalation in Breast Cancer. Ann Surg Oncol 29 (Suppl 3), 570–571 (2022). https://doi.org/10.1245/s10434-021-10699-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10699-3

Search

Navigation